Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia
Aripiprazole is a novel atypical antipsychotic for the treatment of schizophrenia. It is a D2 receptor partial agonist with partial agonist activity at 5-HT1A receptors and antagonist activity at 5-HT2A receptors. The long-term efficacy and safety of aripiprazole (30 mg/d) relative to haloperidol (1...
Gespeichert in:
| Veröffentlicht in: | The international journal of neuropsychopharmacology 2003-12, Vol.6 (4), p.325-337, Article S1461145703003651 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 337 |
|---|---|
| container_issue | 4 |
| container_start_page | 325 |
| container_title | The international journal of neuropsychopharmacology |
| container_volume | 6 |
| creator | Kasper, Siegfried Lerman, Mark N. McQuade, Robert D. Saha, Anutosh Carson, William H. Ali, Mirza Archibald, Donald Ingenito, Gary Marcus, Ronald Pigott, Teresa |
| description | Aripiprazole is a novel atypical antipsychotic for the treatment of schizophrenia. It is a D2 receptor partial agonist with partial agonist activity at 5-HT1A receptors and antagonist activity at 5-HT2A receptors. The long-term efficacy and safety of aripiprazole (30 mg/d) relative to haloperidol (10 mg/d) were investigated in two 52-wk, randomized, double-blind, multicentre studies (using similar protocols which were prospectively identified to be pooled for analysis) in 1294 patients in acute relapse with a diagnosis of chronic schizophrenia and who had previously responded to antipsychotic medications. Aripiprazole demonstrated long-term efficacy that was comparable or superior to haloperidol across all symptoms measures, including significantly greater improvements for PANSS negative subscale scores and MADRS total score (p |
| doi_str_mv | 10.1017/S1461145703003651 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_222349020</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><cupid>10_1017_S1461145703003651</cupid><sourcerecordid>1404323731</sourcerecordid><originalsourceid>FETCH-LOGICAL-c434t-bd2c334a16bacfa8b6ad77e6c6babab6985cc2191dc13b60017521bdddef10e3</originalsourceid><addsrcrecordid>eNp1kMFO4zAQhq0VqwUKD7AXZHEPeOIkJUeEYBcJicNyjyb2uDVK7GC7oPbEo-NuK3FAyAd7PP98I32M_QZxAQLml_-gagCqei6kELKp4Qc7yl9tUQPAwf83FNv-ITuO8VmIsqpl84sd5oZoK9kesfdbY6xCteboNI9oKK25NxyDnewUcOMH4q_xgi9x8BMFq_3AjQ988G5RJAojH9G6RA6dIp4CYRrJpZwZBv9m3YKjWiXigQacIm3ZUS3txk_LQM7iCftpcIh0ur9n7Onu9unmb_Hw-Of-5vqhUJWsUtHrUklZITQ9KoNXfYN6PqdG5Tqfpr2qlSqhBa1A9o3IeuoSeq01GRAkZ-x8h52Cf1lRTN2zXwWXN3ZlWcqqFaXIIdiFVPAxBjLdFOyIYd2B6LbGuy_G88zZHrzqR9KfE3vFOSD3UBz77G9Bn6u_x34AnJSOJA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>222349020</pqid></control><display><type>article</type><title>Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia</title><source>MEDLINE</source><source>Access via Oxford University Press (Open Access Collection)</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Kasper, Siegfried ; Lerman, Mark N. ; McQuade, Robert D. ; Saha, Anutosh ; Carson, William H. ; Ali, Mirza ; Archibald, Donald ; Ingenito, Gary ; Marcus, Ronald ; Pigott, Teresa</creator><creatorcontrib>Kasper, Siegfried ; Lerman, Mark N. ; McQuade, Robert D. ; Saha, Anutosh ; Carson, William H. ; Ali, Mirza ; Archibald, Donald ; Ingenito, Gary ; Marcus, Ronald ; Pigott, Teresa</creatorcontrib><description>Aripiprazole is a novel atypical antipsychotic for the treatment of schizophrenia. It is a D2 receptor partial agonist with partial agonist activity at 5-HT1A receptors and antagonist activity at 5-HT2A receptors. The long-term efficacy and safety of aripiprazole (30 mg/d) relative to haloperidol (10 mg/d) were investigated in two 52-wk, randomized, double-blind, multicentre studies (using similar protocols which were prospectively identified to be pooled for analysis) in 1294 patients in acute relapse with a diagnosis of chronic schizophrenia and who had previously responded to antipsychotic medications. Aripiprazole demonstrated long-term efficacy that was comparable or superior to haloperidol across all symptoms measures, including significantly greater improvements for PANSS negative subscale scores and MADRS total score (p<0.05). The time to discontinuation for any reason was significantly greater with aripiprazole than with haloperidol (p=0.0001). Time to discontinuation due to adverse events or lack of efficacy was significantly greater with aripiprazole than with haloperidol (p=0.0001). Aripiprazole was associated with significantly lower scores on all extrapyramidal symptoms assessments than haloperidol (p<0.001). In summary, aripiprazole demonstrated efficacy equivalent or superior to haloperidol with associated benefits for safety and tolerability. Aripiprazole represents a promising new option for the long-term treatment of schizophrenia.</description><identifier>ISSN: 1461-1457</identifier><identifier>EISSN: 1469-5111</identifier><identifier>DOI: 10.1017/S1461145703003651</identifier><identifier>PMID: 14609439</identifier><language>eng</language><publisher>Cambridge, UK: Cambridge University Press</publisher><subject>Acute Disease ; Adult ; Antipsychotic Agents - adverse effects ; Antipsychotic Agents - therapeutic use ; Aripiprazole ; Double-Blind Method ; Female ; Haloperidol - adverse effects ; Haloperidol - therapeutic use ; Humans ; Long-Term Care ; Male ; Neurologic Examination - drug effects ; Piperazines - adverse effects ; Piperazines - therapeutic use ; Psychiatric Status Rating Scales ; Quinolones - adverse effects ; Quinolones - therapeutic use ; Recurrence ; Schizophrenia - diagnosis ; Schizophrenia - drug therapy ; Schizophrenic Psychology ; Treatment Outcome</subject><ispartof>The international journal of neuropsychopharmacology, 2003-12, Vol.6 (4), p.325-337, Article S1461145703003651</ispartof><rights>2003 Collegium Internationale Neuropsychopharmacologicum</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c434t-bd2c334a16bacfa8b6ad77e6c6babab6985cc2191dc13b60017521bdddef10e3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14609439$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kasper, Siegfried</creatorcontrib><creatorcontrib>Lerman, Mark N.</creatorcontrib><creatorcontrib>McQuade, Robert D.</creatorcontrib><creatorcontrib>Saha, Anutosh</creatorcontrib><creatorcontrib>Carson, William H.</creatorcontrib><creatorcontrib>Ali, Mirza</creatorcontrib><creatorcontrib>Archibald, Donald</creatorcontrib><creatorcontrib>Ingenito, Gary</creatorcontrib><creatorcontrib>Marcus, Ronald</creatorcontrib><creatorcontrib>Pigott, Teresa</creatorcontrib><title>Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia</title><title>The international journal of neuropsychopharmacology</title><addtitle>Int. J. Neuropsychopharm</addtitle><description>Aripiprazole is a novel atypical antipsychotic for the treatment of schizophrenia. It is a D2 receptor partial agonist with partial agonist activity at 5-HT1A receptors and antagonist activity at 5-HT2A receptors. The long-term efficacy and safety of aripiprazole (30 mg/d) relative to haloperidol (10 mg/d) were investigated in two 52-wk, randomized, double-blind, multicentre studies (using similar protocols which were prospectively identified to be pooled for analysis) in 1294 patients in acute relapse with a diagnosis of chronic schizophrenia and who had previously responded to antipsychotic medications. Aripiprazole demonstrated long-term efficacy that was comparable or superior to haloperidol across all symptoms measures, including significantly greater improvements for PANSS negative subscale scores and MADRS total score (p<0.05). The time to discontinuation for any reason was significantly greater with aripiprazole than with haloperidol (p=0.0001). Time to discontinuation due to adverse events or lack of efficacy was significantly greater with aripiprazole than with haloperidol (p=0.0001). Aripiprazole was associated with significantly lower scores on all extrapyramidal symptoms assessments than haloperidol (p<0.001). In summary, aripiprazole demonstrated efficacy equivalent or superior to haloperidol with associated benefits for safety and tolerability. Aripiprazole represents a promising new option for the long-term treatment of schizophrenia.</description><subject>Acute Disease</subject><subject>Adult</subject><subject>Antipsychotic Agents - adverse effects</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Aripiprazole</subject><subject>Double-Blind Method</subject><subject>Female</subject><subject>Haloperidol - adverse effects</subject><subject>Haloperidol - therapeutic use</subject><subject>Humans</subject><subject>Long-Term Care</subject><subject>Male</subject><subject>Neurologic Examination - drug effects</subject><subject>Piperazines - adverse effects</subject><subject>Piperazines - therapeutic use</subject><subject>Psychiatric Status Rating Scales</subject><subject>Quinolones - adverse effects</subject><subject>Quinolones - therapeutic use</subject><subject>Recurrence</subject><subject>Schizophrenia - diagnosis</subject><subject>Schizophrenia - drug therapy</subject><subject>Schizophrenic Psychology</subject><subject>Treatment Outcome</subject><issn>1461-1457</issn><issn>1469-5111</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kMFO4zAQhq0VqwUKD7AXZHEPeOIkJUeEYBcJicNyjyb2uDVK7GC7oPbEo-NuK3FAyAd7PP98I32M_QZxAQLml_-gagCqei6kELKp4Qc7yl9tUQPAwf83FNv-ITuO8VmIsqpl84sd5oZoK9kesfdbY6xCteboNI9oKK25NxyDnewUcOMH4q_xgi9x8BMFq_3AjQ988G5RJAojH9G6RA6dIp4CYRrJpZwZBv9m3YKjWiXigQacIm3ZUS3txk_LQM7iCftpcIh0ur9n7Onu9unmb_Hw-Of-5vqhUJWsUtHrUklZITQ9KoNXfYN6PqdG5Tqfpr2qlSqhBa1A9o3IeuoSeq01GRAkZ-x8h52Cf1lRTN2zXwWXN3ZlWcqqFaXIIdiFVPAxBjLdFOyIYd2B6LbGuy_G88zZHrzqR9KfE3vFOSD3UBz77G9Bn6u_x34AnJSOJA</recordid><startdate>200312</startdate><enddate>200312</enddate><creator>Kasper, Siegfried</creator><creator>Lerman, Mark N.</creator><creator>McQuade, Robert D.</creator><creator>Saha, Anutosh</creator><creator>Carson, William H.</creator><creator>Ali, Mirza</creator><creator>Archibald, Donald</creator><creator>Ingenito, Gary</creator><creator>Marcus, Ronald</creator><creator>Pigott, Teresa</creator><general>Cambridge University Press</general><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope></search><sort><creationdate>200312</creationdate><title>Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia</title><author>Kasper, Siegfried ; Lerman, Mark N. ; McQuade, Robert D. ; Saha, Anutosh ; Carson, William H. ; Ali, Mirza ; Archibald, Donald ; Ingenito, Gary ; Marcus, Ronald ; Pigott, Teresa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c434t-bd2c334a16bacfa8b6ad77e6c6babab6985cc2191dc13b60017521bdddef10e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Acute Disease</topic><topic>Adult</topic><topic>Antipsychotic Agents - adverse effects</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Aripiprazole</topic><topic>Double-Blind Method</topic><topic>Female</topic><topic>Haloperidol - adverse effects</topic><topic>Haloperidol - therapeutic use</topic><topic>Humans</topic><topic>Long-Term Care</topic><topic>Male</topic><topic>Neurologic Examination - drug effects</topic><topic>Piperazines - adverse effects</topic><topic>Piperazines - therapeutic use</topic><topic>Psychiatric Status Rating Scales</topic><topic>Quinolones - adverse effects</topic><topic>Quinolones - therapeutic use</topic><topic>Recurrence</topic><topic>Schizophrenia - diagnosis</topic><topic>Schizophrenia - drug therapy</topic><topic>Schizophrenic Psychology</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kasper, Siegfried</creatorcontrib><creatorcontrib>Lerman, Mark N.</creatorcontrib><creatorcontrib>McQuade, Robert D.</creatorcontrib><creatorcontrib>Saha, Anutosh</creatorcontrib><creatorcontrib>Carson, William H.</creatorcontrib><creatorcontrib>Ali, Mirza</creatorcontrib><creatorcontrib>Archibald, Donald</creatorcontrib><creatorcontrib>Ingenito, Gary</creatorcontrib><creatorcontrib>Marcus, Ronald</creatorcontrib><creatorcontrib>Pigott, Teresa</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><jtitle>The international journal of neuropsychopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kasper, Siegfried</au><au>Lerman, Mark N.</au><au>McQuade, Robert D.</au><au>Saha, Anutosh</au><au>Carson, William H.</au><au>Ali, Mirza</au><au>Archibald, Donald</au><au>Ingenito, Gary</au><au>Marcus, Ronald</au><au>Pigott, Teresa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia</atitle><jtitle>The international journal of neuropsychopharmacology</jtitle><addtitle>Int. J. Neuropsychopharm</addtitle><date>2003-12</date><risdate>2003</risdate><volume>6</volume><issue>4</issue><spage>325</spage><epage>337</epage><pages>325-337</pages><artnum>S1461145703003651</artnum><issn>1461-1457</issn><eissn>1469-5111</eissn><abstract>Aripiprazole is a novel atypical antipsychotic for the treatment of schizophrenia. It is a D2 receptor partial agonist with partial agonist activity at 5-HT1A receptors and antagonist activity at 5-HT2A receptors. The long-term efficacy and safety of aripiprazole (30 mg/d) relative to haloperidol (10 mg/d) were investigated in two 52-wk, randomized, double-blind, multicentre studies (using similar protocols which were prospectively identified to be pooled for analysis) in 1294 patients in acute relapse with a diagnosis of chronic schizophrenia and who had previously responded to antipsychotic medications. Aripiprazole demonstrated long-term efficacy that was comparable or superior to haloperidol across all symptoms measures, including significantly greater improvements for PANSS negative subscale scores and MADRS total score (p<0.05). The time to discontinuation for any reason was significantly greater with aripiprazole than with haloperidol (p=0.0001). Time to discontinuation due to adverse events or lack of efficacy was significantly greater with aripiprazole than with haloperidol (p=0.0001). Aripiprazole was associated with significantly lower scores on all extrapyramidal symptoms assessments than haloperidol (p<0.001). In summary, aripiprazole demonstrated efficacy equivalent or superior to haloperidol with associated benefits for safety and tolerability. Aripiprazole represents a promising new option for the long-term treatment of schizophrenia.</abstract><cop>Cambridge, UK</cop><pub>Cambridge University Press</pub><pmid>14609439</pmid><doi>10.1017/S1461145703003651</doi><tpages>13</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1461-1457 |
| ispartof | The international journal of neuropsychopharmacology, 2003-12, Vol.6 (4), p.325-337, Article S1461145703003651 |
| issn | 1461-1457 1469-5111 |
| language | eng |
| recordid | cdi_proquest_journals_222349020 |
| source | MEDLINE; Access via Oxford University Press (Open Access Collection); EZB-FREE-00999 freely available EZB journals |
| subjects | Acute Disease Adult Antipsychotic Agents - adverse effects Antipsychotic Agents - therapeutic use Aripiprazole Double-Blind Method Female Haloperidol - adverse effects Haloperidol - therapeutic use Humans Long-Term Care Male Neurologic Examination - drug effects Piperazines - adverse effects Piperazines - therapeutic use Psychiatric Status Rating Scales Quinolones - adverse effects Quinolones - therapeutic use Recurrence Schizophrenia - diagnosis Schizophrenia - drug therapy Schizophrenic Psychology Treatment Outcome |
| title | Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T16%3A23%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20safety%20of%20aripiprazole%20vs.%20haloperidol%20for%20long-term%20maintenance%20treatment%20following%20acute%20relapse%20of%20schizophrenia&rft.jtitle=The%20international%20journal%20of%20neuropsychopharmacology&rft.au=Kasper,%20Siegfried&rft.date=2003-12&rft.volume=6&rft.issue=4&rft.spage=325&rft.epage=337&rft.pages=325-337&rft.artnum=S1461145703003651&rft.issn=1461-1457&rft.eissn=1469-5111&rft_id=info:doi/10.1017/S1461145703003651&rft_dat=%3Cproquest_cross%3E1404323731%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=222349020&rft_id=info:pmid/14609439&rft_cupid=10_1017_S1461145703003651&rfr_iscdi=true |